TD Asset Management Inc purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 10,132 shares of the company’s stock, valued at approximately $121,000.
Other institutional investors have also bought and sold shares of the company. Parallel Advisors LLC boosted its holdings in shares of Cellebrite DI by 75.0% in the fourth quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock worth $30,000 after acquiring an additional 1,500 shares during the period. Quarry LP purchased a new stake in shares of Cellebrite DI in the fourth quarter worth about $36,000. nVerses Capital LLC purchased a new stake in shares of Cellebrite DI in the second quarter worth about $103,000. Central Asset Investments & Management Holdings HK Ltd purchased a new stake in shares of Cellebrite DI in the fourth quarter worth about $113,000. Finally, Hennessy Advisors Inc. bought a new position in shares of Cellebrite DI in the fourth quarter valued at approximately $131,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.
Analysts Set New Price Targets
Several analysts have issued reports on the stock. Lake Street Capital increased their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $14.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Needham & Company LLC upped their target price on Cellebrite DI from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Craig Hallum lifted their target price on shares of Cellebrite DI from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $17.33.
Cellebrite DI Price Performance
Shares of Cellebrite DI stock opened at $17.52 on Tuesday. The stock has a market capitalization of $3.61 billion, a P/E ratio of -30.21, a price-to-earnings-growth ratio of 2.33 and a beta of 1.52. Cellebrite DI Ltd. has a one year low of $6.36 and a one year high of $17.61. The business’s 50 day simple moving average is $14.70 and its two-hundred day simple moving average is $12.53.
Cellebrite DI (NASDAQ:CLBT – Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The business had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $91.94 million. During the same quarter in the prior year, the company posted $0.05 EPS. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year. Sell-side analysts expect that Cellebrite DI Ltd. will post 0.31 earnings per share for the current fiscal year.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
- Five stocks we like better than Cellebrite DI
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Best Stocks Under $10.00
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- High Flyers: 3 Natural Gas Stocks for March 2022
- 5 Oversold Stocks to Buy Right Now
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.